Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Mallinckrodt
McKinsey
Dow

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 9,693,968

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,693,968
Title:Cholestosome vesicles for incorporation of molecules into chylomicrons
Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (\"cholestosome\") consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
Inventor(s): Schentag; Jerome J. (Amherst, NY), McCourt; Mary P. (Amherst, NY), Mielnicki; Lawrencee (Buffalo, NY), Hughes; Julie (Williamsville, NY)
Assignee:
Application Number:14/776,308
Patent Claims:see list of patent claims

Details for Patent 9,693,968

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 2000-04-20 ⤷  Free Forever Trial 2033-03-14
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 2007-04-25 ⤷  Free Forever Trial 2033-03-14
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2033-03-14
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2033-03-14
Abbvie Inc. HUMIRA adalimumab Injection 125057 2002-12-31 ⤷  Free Forever Trial 2033-03-14
Abbvie Inc. HUMIRA adalimumab Injection 125057 2008-02-21 ⤷  Free Forever Trial 2033-03-14
Abbvie Inc. HUMIRA adalimumab Injection 125057 2013-04-24 ⤷  Free Forever Trial 2033-03-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.